Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALI A KARRAR

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1871520239
CMS profile
311409
Location
GRAND BLANC, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,819.50

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,167.09 142
Travel and Lodging $2,459.26 5
Education $193.15 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALI A KARRAR

NPI 1871520239 · CMS profile ID 311409

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GRAND BLANC, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871520239?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALI A KARRAR, NPI 1871520239, CMS profile ID 311409. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871520239?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ALI A KARRAR, NPI 1871520239, CMS profile ID 311409. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871520239?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ALI A KARRAR, NPI 1871520239, CMS profile ID 311409, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1871520239?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $5,819.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $978.0109/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012249643 CMS
Janssen Biotech, Inc. $12.0509/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701431 CMS
AstraZeneca Pharmaceuticals LP $14.4308/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011778033 CMS
ABBVIE INC. $9.6308/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997608187 CMS
Sandoz Inc. $32.0608/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028943407 CMS
Actelion Pharmaceuticals US, Inc. $24.5108/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988767305 CMS
AstraZeneca Pharmaceuticals LP $30.2208/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015960983 CMS
Alexion Pharmaceuticals, Inc. $23.7108/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016992117 CMS
Amgen Inc. $11.1708/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788439 CMS
ABBVIE INC. $24.0908/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997608185 CMS
Janssen Biotech, Inc. $17.5508/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701433 CMS
Janssen Biotech, Inc. $23.4908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701455 CMS
Amgen Inc. $29.5908/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788491 CMS
GlaxoSmithKline, LLC. $12.8208/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002983472 CMS
Organon LLC $10.2808/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046800085 CMS
Janssen Biotech, Inc. $13.9808/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701439 CMS
ABBVIE INC. $14.2708/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997608183 CMS
AstraZeneca Pharmaceuticals LP $15.1408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016065645 CMS
Amgen Inc. $23.3607/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788389 CMS
Janssen Biotech, Inc. $79.9907/26/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701427 CMS
Amgen Inc. $26.6407/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788435 CMS
Fresenius Kabi USA, LLC $18.4107/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060095525 CMS
Amgen Inc. $23.5707/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020529989 CMS
Amgen Inc. $10.6707/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788479 CMS
Horizon Therapeutics plc $15.6207/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987027993 CMS
Mylan Institutional Inc. $17.0507/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039009863 CMS
Amgen Inc. $19.4307/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788373 CMS
Organon LLC $11.8307/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046800069 CMS
Janssen Biotech, Inc. $12.8707/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701451 CMS
PFIZER INC. $22.5007/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050526839 CMS
Aurinia Pharma U.S., Inc. $18.7107/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057737067 CMS
Novartis Pharmaceuticals Corporation $23.3407/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991990633 CMS
ABBVIE INC. $7.8307/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997608181 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.2707/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996562659 CMS
Amgen Inc. $8.9206/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788431 CMS
Janssen Biotech, Inc. $18.0606/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701463 CMS
AstraZeneca UK Limited $24.9506/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016982193 CMS
AstraZeneca UK Limited $24.9506/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016990941 CMS
AstraZeneca UK Limited $127.5706/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017016681 CMS
AstraZeneca UK Limited $134.8606/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017083625 CMS
AstraZeneca UK Limited $22.0006/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016974579 CMS
AstraZeneca UK Limited $12.5806/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016981301 CMS
AstraZeneca UK Limited $640.8306/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016984521 CMS
AstraZeneca UK Limited $254.8706/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016996213 CMS
AstraZeneca UK Limited $24.9506/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017064515 CMS
ABBVIE INC. $25.9906/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997608179 CMS
Janssen Biotech, Inc. $11.2306/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988701457 CMS
Amgen Inc. $24.0906/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019788487 CMS
AstraZeneca UK Limited $416.2606/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017004613 CMS
Organon LLC $25.3406/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046800077 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,298.75 202
PY2020 $1,827.17 112
PY2021 $2,179.07 138
PY2022 $2,385.12 140
PY2023 $5,819.50 150
PY2024 $5,391.20 169
PY2025 $4,682.13 184

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $249,511.34 31
PY2024 Recipient $1,630.00 1
PY2024 Principal investigator $352,557.63 59
PY2023 Recipient $1,568.92 13
PY2023 Principal investigator $521,000.53 40
PY2022 Principal investigator $699,757.08 74
PY2021 Principal investigator $329,801.24 59
PY2020 Principal investigator $153,916.82 66
PY2019 Recipient $1,884.03 12
PY2019 Principal investigator $162,185.26 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,789.80 12/17/2025 Non-covered Recipient Entity
AA MRC LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289776
Principal investigator 1 ABBVIE INC. $2,341.80 12/04/2025 Non-covered Recipient Entity
AA MRC LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527114
Principal investigator 1 ABBVIE INC. $5,142.00 12/04/2025 Non-covered Recipient Entity
AA MRC LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527116
Principal investigator 1 ABBVIE INC. $2,750.80 12/04/2025 Non-covered Recipient Entity
AA MRC LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527208
Principal investigator 1 ABBVIE INC. $10,016.50 11/05/2025 Non-covered Recipient Entity
AA MRC LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522165
Principal investigator 1 ABBVIE INC. $2,439.00 11/04/2025 Non-covered Recipient Entity
AA MRC LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520525
Principal investigator 1 ABBVIE INC. $1,341.80 11/04/2025 Non-covered Recipient Entity
AA MRC LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520527
Principal investigator 1 ABBVIE INC. $2,054.60 10/09/2025 Non-covered Recipient Entity
AA MRC LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202514015
Principal investigator 1 ABBVIE INC. $2,799.00 10/09/2025 Non-covered Recipient Entity
AA MRC LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202514017
Principal investigator 1 ABBVIE INC. $770.25 10/09/2025 Non-covered Recipient Entity
AA MRC LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202514181
Principal investigator 1 Daiichi Sankyo Inc. $16.00 10/01/2025 Non-covered Recipient Entity
AA MRC LLC Ahmed Arif Medical Research Center
DS7011-107 No dispute reported 06/30/2026 1223362806
Principal investigator 1 ABBVIE INC. $2,655.00 09/03/2025 Non-covered Recipient Entity
AA MRC LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202507377
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,268.68 08/19/2025 Non-covered Recipient Entity
AA MEDICAL RESEARCH CENTER
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190310498
Principal investigator 1 ABBVIE INC. $2,487.00 08/05/2025 Non-covered Recipient Entity
AA MRC LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501204
Principal investigator 1 ABBVIE INC. $1,980.20 07/02/2025 Non-covered Recipient Entity
AA MRC LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494079
Principal investigator 1 ABBVIE INC. $13,218.00 07/02/2025 Non-covered Recipient Entity
AA MRC LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494081
Principal investigator 1 ABBVIE INC. $10,903.00 06/03/2025 Non-covered Recipient Entity
AA MRC LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202488589
Principal investigator 1 ABBVIE INC. $2,141.00 05/06/2025 Non-covered Recipient Entity
AA MRC LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481463
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 03/25/2025 Non-covered Recipient Entity
AA MRC LLC
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190310879
Principal investigator 1 ABBVIE INC. $2,439.00 03/06/2025 Non-covered Recipient Entity
AA MRC LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202457797
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,688.24 02/27/2025 Non-covered Recipient Entity
AA MRC LLC
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190310905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 02/26/2025 Non-covered Recipient Entity
AA MRC LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223275687
Principal investigator 1 Eli Lilly and Company $18,576.00 02/11/2025 Non-covered Recipient Entity
AA MRC LLC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877349
Principal investigator 1 ABBVIE INC. $4,824.60 02/05/2025 Non-covered Recipient Entity
AA MRC LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202444323
Principal investigator 1 ABBVIE INC. $3,908.00 02/05/2025 Non-covered Recipient Entity
AA MRC LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444327
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,797.00 01/28/2025 Non-covered Recipient Entity
AA MRC LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190310903
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,044.71 01/28/2025 Non-covered Recipient Entity
AA MRC LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190310907
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $28,912.00 01/21/2025 Non-covered Recipient Entity
Aa Medical Research Center
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235999423
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,131.86 01/09/2025 Non-covered Recipient Entity
AA MEDICAL RESEARCH CENTER
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190310496
Principal investigator 1 AstraZeneca UK Limited $7,420.50 01/08/2025 Non-covered Recipient Entity
AA MRC LLC
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185554302
Principal investigator 1 ABBVIE INC. $2,655.00 01/02/2025 Non-covered Recipient Entity
AA MRC LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202433974